Detected circulating tumor DNA was strongly associated with evidence of disease (OR 74.0) and positively correlated with tumor burden (Spearman R = 0.844) in patients with adrenocortical carcinoma.
Cohort (n=20)
No
Does circulating tumor DNA (ctDNA) testing correlate with disease status and tumor burden in patients with adrenocortical carcinoma?
ctDNA testing demonstrates high sensitivity and specificity for detecting disease and correlates strongly with tumor burden in adrenocortical carcinoma, supporting its potential use for disease monitoring.
Odds Ratio: 74 (95% CI 9–3438)
p-value: p=<0.001
Adrenocortical carcinoma (ACC) is a rare malignancy with high recurrence rates. Circulating tumor DNA (ctDNA) is a minimally invasive, blood-based biomarker with multiple oncologic applications. The role of ctDNA in ACC care remains understudied. This retrospective, single-institution, study evaluated real-world use of ctDNA testing in patients with ACC and its correlation with imaging-based tumor burden. Patients with ACC (≥ 18 years) who underwent ctDNA testing via a clinically validated, personalized, tumor-informed assay (Signatera™, Natera) during their disease course were reviewed, and clinical data were obtained from the medical records. ctDNA results were tested for association with disease status and tumor burden determined by concurrent imaging and clinical evaluation. Twenty patients (55% male) were included; the median age at first ctDNA assessment was 58.3 years (range, 23.3-81.1). A total of 87 ctDNA tests were analyzed (median, 4 tests/patient; interquartile range IQR, 1-6). The median ctDNA level was 1.27 mean tumor molecules/mL (IQR, 0.05-22.86). Detected ctDNA was strongly associated with evidence of disease (odds ratio, 74; 95% confidence interval, 9-3438). The ctDNA assay demonstrated high sensitivity (88%), specificity (91.7%), and overall accuracy (88.5%), with a positive post-test probability of 98% and a negative post-test probability of 45%. In addition, ctDNA levels were positively correlated with tumor burden (Spearman R = 0.844; p < 0.001). These findings support the potential value of ctDNA testing for disease monitoring in ACC and it may support a more personalized approach to this rare disease.
Balderrama-Brondani et al. (Fri,) conducted a cohort in Adrenocortical carcinoma (n=20). Circulating tumor DNA (ctDNA) testing vs. Undetectable ctDNA was evaluated on Association between detected ctDNA and evidence of disease (OR 74.0, 95% CI 9.0-3438.0, p=<0.001). Detected circulating tumor DNA was strongly associated with evidence of disease (OR 74.0) and positively correlated with tumor burden (Spearman R = 0.844) in patients with adrenocortical carcinoma.